IYUZEH Drug Patent Profile
✉ Email this page to a colleague
When do Iyuzeh patents expire, and what generic alternatives are available?
Iyuzeh is a drug marketed by Thea Pharma and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-four patent family members in twenty-seven countries.
The generic ingredient in IYUZEH is latanoprost. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iyuzeh
A generic version of IYUZEH was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for IYUZEH?
- What are the global sales for IYUZEH?
- What is Average Wholesale Price for IYUZEH?
Summary for IYUZEH
| International Patents: | 34 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 7,403 |
| Drug Prices: | Drug price information for IYUZEH |
| What excipients (inactive ingredients) are in IYUZEH? | IYUZEH excipients list |
| DailyMed Link: | IYUZEH at DailyMed |
US Patents and Regulatory Information for IYUZEH
IYUZEH is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thea Pharma | IYUZEH | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 216472-001 | Dec 13, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IYUZEH
See the table below for patents covering IYUZEH around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011273549 | ⤷ Start Trial | |
| Brazil | 112012033435 | ⤷ Start Trial | |
| Canada | 2802816 | ⤷ Start Trial | |
| Chile | 2012003684 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IYUZEH
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0364417 | SPC/GB97/014 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
| 0364417 | 97C0128 | France | ⤷ Start Trial | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
| 0364417 | 9690031-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: LATANOPROST |
| 0364417 | 97C0111 | Belgium | ⤷ Start Trial | PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
DrugChatter Q&A for IYUZEH
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch